Literature DB >> 27009433

Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.

Marija Bosilkovska1, Caroline Samer1,2, Julien Déglon3,4, Aurélien Thomas3, Bernhard Walder5, Jules Desmeules1,2, Youssef Daali1,2.   

Abstract

Cytochrome P450 (CYP) activity can be assessed using a 'cocktail' phenotyping approach. Recently, we have developed a cocktail (Geneva cocktail) which combines the use of low-dose probes with a low-invasiveness dried blood spots (DBS) sampling technique and a single analytical method for the phenotyping of six major CYP isoforms. We have previously demonstrated that modulation of CYP activity after pre-treatment with CYP inhibitors/inducer could be reliably predicted using Geneva cocktail. To further validate this cocktail, in this study, we have verified whether probe drugs contained in the latter cause mutual drug-drug interactions. In a randomized, four-way, Latin-square crossover study, 30 healthy volunteers received low-dose caffeine, flurbiprofen, omeprazole, dextromethorphan and midazolam (a previously validated combination with no mutual drug-drug interactions); fexofenadine alone; bupropion alone; or all seven drugs simultaneously (Geneva cocktail). Pharmacokinetic profiles of the probe drugs and their metabolites were determined in DBS samples using both conventional micropipette sampling and new microfluidic device allowing for self-sampling. The 90% confidence intervals for the geometric mean ratios of AUC metabolite/AUC probe for CYP probes administered alone or within Geneva cocktail fell within the 0.8-1.25 bioequivalence range indicating the absence of pharmacokinetic interaction. The same result was observed for the chosen phenotyping indices, that is metabolic ratios at 2 hr (CYP1A2, CYP3A) or 3 hr (CYP2B6, CYP2C9, CYP2C19, CYP2D6) post-cocktail administration. DBS sampling could successfully be performed using a new microfluidic device. In conclusion, Geneva cocktail combined with an innovative DBS sampling device can be used routinely as a test for simultaneous CYP phenotyping.
© 2016 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27009433     DOI: 10.1111/bcpt.12586

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  15 in total

Review 1.  Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.

Authors:  Gaëlle Magliocco; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

2.  Sample size determination in bioequivalence studies using statistical assurance.

Authors:  A Ring; B Lang; C Kazaroho; D Labes; R Schall; H Schütz
Journal:  Br J Clin Pharmacol       Date:  2019-08-13       Impact factor: 4.335

3.  Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device.

Authors:  Tom C Zwart; Sumit R M Gokoel; Paul J M van der Boog; Johan W de Fijter; Dina M Kweekel; Jesse J Swen; Henk-Jan Guchelaar; Dirk Jan A R Moes
Journal:  Br J Clin Pharmacol       Date:  2018-10-15       Impact factor: 4.335

4.  Evaluation of phenoconversion phenomenon in obese patients: the effects of bariatric surgery on the CYP450 activity "a protocol for a case-control pharmacokinetic study".

Authors:  Hengameh Ghasim; Mohammadreza Rouini; Kheirollah Gholami; Farnoosh Larti; Saeed Safari; Yalda H Ardakani
Journal:  J Diabetes Metab Disord       Date:  2021-07-31

5.  Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions.

Authors:  Flavia Storelli; Jules Desmeules; Youssef Daali
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-07-03

6.  No Clinically Relevant Interactions of St. John's Wort Extract Ze 117 Low in Hyperforin With Cytochrome P450 Enzymes and P-glycoprotein.

Authors:  Catherine Zahner; Esther Kruttschnitt; Julia Uricher; Michael Lissy; Martin Hirsch; Simon Nicolussi; Stephan Krähenbühl; Jürgen Drewe
Journal:  Clin Pharmacol Ther       Date:  2019-03-23       Impact factor: 6.875

Review 7.  When the Safe Alternative Is Not That Safe: Tramadol Prescribing in Children.

Authors:  Frédérique Rodieux; Laszlo Vutskits; Klara M Posfay-Barbe; Walid Habre; Valérie Piguet; Jules A Desmeules; Caroline F Samer
Journal:  Front Pharmacol       Date:  2018-03-05       Impact factor: 5.810

Review 8.  Interpretation of Drug Interaction Using Systemic and Local Tissue Exposure Changes.

Authors:  Young Hee Choi
Journal:  Pharmaceutics       Date:  2020-05-02       Impact factor: 6.321

9.  Evaluating the effect of type 2 diabetes mellitus on CYP450 enzymes and P-gp activities, before and after glycemic control: A protocol for a case-control pharmacokinetic study.

Authors:  Navid Neyshaburinezhad; Mohammadreza Rouini; Nooshin Shirzad; Alireza Esteghamati; Manouchehr Nakhjavani; Soha Namazi; Yalda H Ardakani
Journal:  MethodsX       Date:  2020-03-07

10.  Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail.

Authors:  Marija Bosilkovska; Gaelle Magliocco; Jules Desmeules; Caroline Samer; Youssef Daali
Journal:  J Pers Med       Date:  2019-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.